{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:09:26Z","timestamp":1793239766088,"version":"4.5.0"},"reference-count":224,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,9,9]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.<\/jats:p>","DOI":"10.1136\/jitc-2021-002873","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T15:12:14Z","timestamp":1634137934000},"page":"e002873","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["Immunological configuration of ovarian carcinoma: features and impact on disease outcome"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct04503980","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01567891","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03017131","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02498912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03132922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03412877","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-479X","authenticated-orcid":false,"given":"Jitka","family":"Fucikova","sequence":"first","affiliation":[{"name":"Sotio Biotech, Prague, Czech Republic"},{"name":"Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-4339","authenticated-orcid":false,"given":"An","family":"Coosemans","sequence":"additional","affiliation":[{"name":"Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Orsulic","sequence":"additional","affiliation":[{"name":"UCLA David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-9356","authenticated-orcid":false,"given":"David","family":"Cibula","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Center, Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[{"name":"Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA"},{"name":"Sandra and Edward Meyer Cancer Center, New York, NY, USA"},{"name":"Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Spisek","sequence":"additional","affiliation":[{"name":"Sotio Biotech, Prague, Czech Republic"},{"name":"Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"2025100308562026000_9.10.e002873.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2025100308562026000_9.10.e002873.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz062"},{"key":"2025100308562026000_9.10.e002873.3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006412"},{"key":"2025100308562026000_9.10.e002873.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00577","article-title":"The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer","volume":"8","author":"Zhou","year":"2018","journal-title":"Front Oncol"},{"key":"2025100308562026000_9.10.e002873.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.01.003"},{"key":"2025100308562026000_9.10.e002873.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.01.053"},{"key":"2025100308562026000_9.10.e002873.7","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100308562026000_9.10.e002873.8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025100308562026000_9.10.e002873.9","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in ovarian cancer: are we there yet?","volume":"37","author":"Kandalaft","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100308562026000_9.10.e002873.10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025100308562026000_9.10.e002873.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397"},{"key":"2025100308562026000_9.10.e002873.12","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025100308562026000_9.10.e002873.13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.11.7338"},{"key":"2025100308562026000_9.10.e002873.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0387"},{"key":"2025100308562026000_9.10.e002873.15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/cas.12445","article-title":"Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment","volume":"105","author":"Tanizaki","year":"2014","journal-title":"Cancer Sci"},{"key":"2025100308562026000_9.10.e002873.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01273","article-title":"Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer","volume":"10","author":"Baert","year":"2019","journal-title":"Front Immunol"},{"key":"2025100308562026000_9.10.e002873.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2271"},{"key":"2025100308562026000_9.10.e002873.18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.18801"},{"key":"2025100308562026000_9.10.e002873.19","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191869","article-title":"Tissue-Resident macrophages in omentum promote metastatic spread of ovarian cancer","volume":"217","author":"Etzerodt","year":"2020","journal-title":"J Exp Med"},{"key":"2025100308562026000_9.10.e002873.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000979","article-title":"M2-Like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer","volume":"8","author":"Hensler","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308562026000_9.10.e002873.21","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0446-3"},{"key":"2025100308562026000_9.10.e002873.22","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1040960"},{"key":"2025100308562026000_9.10.e002873.23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0284"},{"key":"2025100308562026000_9.10.e002873.24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","article-title":"Single-Cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer","volume":"39","author":"Hornburg","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100308562026000_9.10.e002873.25","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat Med"},{"key":"2025100308562026000_9.10.e002873.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109165","article-title":"Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics","volume":"35","author":"Olalekan","year":"2021","journal-title":"Cell Rep"},{"key":"2025100308562026000_9.10.e002873.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.08.013"},{"key":"2025100308562026000_9.10.e002873.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.039"},{"key":"2025100308562026000_9.10.e002873.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0583-5"},{"key":"2025100308562026000_9.10.e002873.30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102"},{"key":"2025100308562026000_9.10.e002873.31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605274"},{"key":"2025100308562026000_9.10.e002873.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.04.009"},{"key":"2025100308562026000_9.10.e002873.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1877"},{"key":"2025100308562026000_9.10.e002873.34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-422"},{"key":"2025100308562026000_9.10.e002873.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"2025100308562026000_9.10.e002873.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.07.105"},{"key":"2025100308562026000_9.10.e002873.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111757","article-title":"Analysis of Foxp3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers","volume":"9","author":"Hermans","year":"2014","journal-title":"PLoS One"},{"key":"2025100308562026000_9.10.e002873.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.11.020"},{"key":"2025100308562026000_9.10.e002873.39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/0284186X.2019.1711173","article-title":"Favorable prognostic impact of natural killer cells and T cells in high-grade serous ovarian carcinoma","volume":"59","author":"Henriksen","year":"2020","journal-title":"Acta Oncol"},{"key":"2025100308562026000_9.10.e002873.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"2025100308562026000_9.10.e002873.41","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.191"},{"key":"2025100308562026000_9.10.e002873.42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/cgt.2015.7","article-title":"Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer","volume":"22","author":"Zhang","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"2025100308562026000_9.10.e002873.43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424672","article-title":"Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells","volume":"7","author":"Lieber","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100308562026000_9.10.e002873.44","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025100308562026000_9.10.e002873.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4175"},{"key":"2025100308562026000_9.10.e002873.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3687"},{"key":"2025100308562026000_9.10.e002873.47","doi-asserted-by":"crossref","first-page":"75130","DOI":"10.18632\/oncotarget.12077","article-title":"CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCR\u03b1\u03b2+ CD8\u03b1\u03b2+ T cells that can be targeted for cancer immunotherapy","volume":"7","author":"Komdeur","year":"2016","journal-title":"Oncotarget"},{"key":"2025100308562026000_9.10.e002873.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0206-z"},{"key":"2025100308562026000_9.10.e002873.49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7072"},{"key":"2025100308562026000_9.10.e002873.50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"Tim3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025100308562026000_9.10.e002873.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7"},{"key":"2025100308562026000_9.10.e002873.52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"2025100308562026000_9.10.e002873.53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1244"},{"key":"2025100308562026000_9.10.e002873.54","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"2025100308562026000_9.10.e002873.55","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179"},{"key":"2025100308562026000_9.10.e002873.56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1866"},{"key":"2025100308562026000_9.10.e002873.57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1753-x"},{"key":"2025100308562026000_9.10.e002873.58","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-012-0122-y"},{"key":"2025100308562026000_9.10.e002873.59","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27759"},{"key":"2025100308562026000_9.10.e002873.60","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0479"},{"key":"2025100308562026000_9.10.e002873.61","doi-asserted-by":"publisher","DOI":"10.1038\/nature10169"},{"key":"2025100308562026000_9.10.e002873.62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0554"},{"key":"2025100308562026000_9.10.e002873.63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025100308562026000_9.10.e002873.64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.ircmb.2019.07.008","article-title":"Interplay between dendritic cells and cancer cells","volume":"348","author":"Martinek","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025100308562026000_9.10.e002873.65","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28335"},{"key":"2025100308562026000_9.10.e002873.66","doi-asserted-by":"crossref","first-page":"44534","DOI":"10.18632\/oncotarget.10003","article-title":"TGF-\u03b21 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"2025100308562026000_9.10.e002873.67","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.7150\/jca.20314","article-title":"Immune cell population in ovarian tumor microenvironment","volume":"8","author":"Cai","year":"2017","journal-title":"J Cancer"},{"key":"2025100308562026000_9.10.e002873.68","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181bb70c6"},{"key":"2025100308562026000_9.10.e002873.69","doi-asserted-by":"publisher","DOI":"10.1038\/nm863"},{"key":"2025100308562026000_9.10.e002873.70","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.172"},{"key":"2025100308562026000_9.10.e002873.71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.ircmb.2019.10.001","article-title":"Transcriptional control of dendritic cell development and functions","volume":"349","author":"Amon","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025100308562026000_9.10.e002873.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.11.010"},{"key":"2025100308562026000_9.10.e002873.73","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6"},{"key":"2025100308562026000_9.10.e002873.74","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1665460","article-title":"Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCS and higher CXCL17 expression in human epithelial ovarian cancer","volume":"8","author":"MacGregor","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100308562026000_9.10.e002873.75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.ircmb.2019.10.002","article-title":"The versatile plasmacytoid dendritic cell: function, heterogeneity, and plasticity","volume":"349","author":"Leylek","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025100308562026000_9.10.e002873.76","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0812397"},{"key":"2025100308562026000_9.10.e002873.77","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2011-5423"},{"key":"2025100308562026000_9.10.e002873.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.07.015"},{"key":"2025100308562026000_9.10.e002873.79","doi-asserted-by":"publisher","DOI":"10.1038\/nm1201-1339"},{"key":"2025100308562026000_9.10.e002873.80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02393","article-title":"Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications","volume":"10","author":"Fucikova","year":"2019","journal-title":"Front Immunol"},{"key":"2025100308562026000_9.10.e002873.81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0234"},{"key":"2025100308562026000_9.10.e002873.82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3368"},{"key":"2025100308562026000_9.10.e002873.83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2762"},{"key":"2025100308562026000_9.10.e002873.84","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.00369","article-title":"Cd38 predicts favorable prognosis by enhancing immune infiltration and antitumor immunity in the epithelial ovarian cancer microenvironment","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Genet"},{"key":"2025100308562026000_9.10.e002873.85","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-016-0232-0"},{"key":"2025100308562026000_9.10.e002873.86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2025100308562026000_9.10.e002873.87","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1611OC"},{"key":"2025100308562026000_9.10.e002873.88","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001323"},{"key":"2025100308562026000_9.10.e002873.89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0081"},{"key":"2025100308562026000_9.10.e002873.90","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"2025100308562026000_9.10.e002873.91","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020305","article-title":"Opposite macrophage polarization in different subsets of ovarian cancer: observation from a pilot study","volume":"9","author":"Vankerckhoven","year":"2020","journal-title":"Cells"},{"key":"2025100308562026000_9.10.e002873.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.06.001"},{"key":"2025100308562026000_9.10.e002873.93","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.169"},{"key":"2025100308562026000_9.10.e002873.94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87252"},{"key":"2025100308562026000_9.10.e002873.95","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","article-title":"Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis","volume":"147","author":"Yuan","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025100308562026000_9.10.e002873.96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038541"},{"key":"2025100308562026000_9.10.e002873.97","doi-asserted-by":"publisher","DOI":"10.7785\/tcrt.2012.500312"},{"key":"2025100308562026000_9.10.e002873.98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079769","article-title":"High MUC2 expression in ovarian cancer is inversely associated with the M1\/M2 ratio of tumor-associated macrophages and patient survival time","volume":"8","author":"He","year":"2013","journal-title":"PLoS One"},{"key":"2025100308562026000_9.10.e002873.99","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0118"},{"key":"2025100308562026000_9.10.e002873.100","first-page":"9428","article-title":"B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer","volume":"8","author":"Zhou","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2025100308562026000_9.10.e002873.101","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-7-19"},{"key":"2025100308562026000_9.10.e002873.102","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63276-1","article-title":"Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients","volume":"10","author":"Macci\u00f2","year":"2020","journal-title":"Sci Rep"},{"key":"2025100308562026000_9.10.e002873.103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/bs.ircmb.2018.07.001","article-title":"Macrophages: their untold story in T cell activation and function","volume":"342","author":"Guerriero","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025100308562026000_9.10.e002873.104","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04987-y","article-title":"Fabp4 as a key determinant of metastatic potential of ovarian cancer","volume":"9","author":"Gharpure","year":"2018","journal-title":"Nat Commun"},{"key":"2025100308562026000_9.10.e002873.105","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2465"},{"key":"2025100308562026000_9.10.e002873.106","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2492"},{"key":"2025100308562026000_9.10.e002873.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.02.016"},{"key":"2025100308562026000_9.10.e002873.108","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-Derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2025100308562026000_9.10.e002873.109","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506"},{"key":"2025100308562026000_9.10.e002873.110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00691","article-title":"Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer","volume":"10","author":"Ok\u0142a","year":"2019","journal-title":"Front Immunol"},{"key":"2025100308562026000_9.10.e002873.111","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20164"},{"key":"2025100308562026000_9.10.e002873.112","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.celrep.2017.09.018","article-title":"Prostaglandin E2 leads to the acquisition of DNMT3A-Dependent tolerogenic functions in human myeloid-derived suppressor cells","volume":"21","author":"Rodr\u00edguez-Ubreva","year":"2017","journal-title":"Cell Rep"},{"key":"2025100308562026000_9.10.e002873.113","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2449"},{"key":"2025100308562026000_9.10.e002873.114","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1111\/febs.15311","article-title":"Myeloid-Derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2\/p-STAT3 signalling pathway","volume":"287","author":"Li","year":"2020","journal-title":"Febs J"},{"key":"2025100308562026000_9.10.e002873.115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03966-7"},{"key":"2025100308562026000_9.10.e002873.116","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00262-020-02628-2","article-title":"The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer","volume":"69","author":"Komura","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2025100308562026000_9.10.e002873.117","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02389-7","article-title":"Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes\/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1","volume":"18","author":"Ok\u0142a","year":"2020","journal-title":"J Transl Med"},{"key":"2025100308562026000_9.10.e002873.118","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2460"},{"key":"2025100308562026000_9.10.e002873.119","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121277"},{"key":"2025100308562026000_9.10.e002873.120","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0157"},{"key":"2025100308562026000_9.10.e002873.121","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci Immunol"},{"key":"2025100308562026000_9.10.e002873.122","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15186-z","article-title":"Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies","volume":"11","author":"Mabuchi","year":"2020","journal-title":"Nat Commun"},{"key":"2025100308562026000_9.10.e002873.123","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.08.025"},{"key":"2025100308562026000_9.10.e002873.124","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0880"},{"key":"2025100308562026000_9.10.e002873.125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer-natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025100308562026000_9.10.e002873.126","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-Infiltrating natural killer cells","volume":"11","author":"C\u00f3zar","year":"2021","journal-title":"Cancer Discov"},{"key":"2025100308562026000_9.10.e002873.127","doi-asserted-by":"crossref","first-page":"34810","DOI":"10.18632\/oncotarget.26199","article-title":"Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients","volume":"9","author":"Hoogstad-van Evert","year":"2018","journal-title":"Oncotarget"},{"key":"2025100308562026000_9.10.e002873.128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00010"},{"key":"2025100308562026000_9.10.e002873.129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.01.019"},{"key":"2025100308562026000_9.10.e002873.130","first-page":"5233","article-title":"Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis","volume":"32","author":"Krockenberger","year":"2012","journal-title":"Anticancer Res"},{"key":"2025100308562026000_9.10.e002873.131","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1001224"},{"key":"2025100308562026000_9.10.e002873.132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.01.004"},{"key":"2025100308562026000_9.10.e002873.133","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-4653"},{"key":"2025100308562026000_9.10.e002873.134","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1"},{"key":"2025100308562026000_9.10.e002873.135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110406","article-title":"Cancer associated fibroblasts: Naughty neighbors that drive ovarian cancer progression","volume":"10","author":"Dasari","year":"2018","journal-title":"Cancers"},{"key":"2025100308562026000_9.10.e002873.136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004992"},{"key":"2025100308562026000_9.10.e002873.137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45273"},{"key":"2025100308562026000_9.10.e002873.138","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-013-0140-4"},{"key":"2025100308562026000_9.10.e002873.139","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317712592"},{"key":"2025100308562026000_9.10.e002873.140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pharmthera.2019.04.004","article-title":"Stress responses in stromal cells and tumor homeostasis","volume":"200","author":"Vitale","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2025100308562026000_9.10.e002873.141","doi-asserted-by":"publisher","DOI":"10.1593\/neo.101720"},{"key":"2025100308562026000_9.10.e002873.142","doi-asserted-by":"publisher","DOI":"10.1593\/neo.121228"},{"key":"2025100308562026000_9.10.e002873.143","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0206"},{"key":"2025100308562026000_9.10.e002873.144","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cmet.2018.08.007","article-title":"Fibroblasts mobilize tumor cell glycogen to promote proliferation and metastasis","volume":"29","author":"Curtis","year":"2019","journal-title":"Cell Metab"},{"key":"2025100308562026000_9.10.e002873.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.01.029"},{"key":"2025100308562026000_9.10.e002873.146","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-5016"},{"key":"2025100308562026000_9.10.e002873.147","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.02.034"},{"key":"2025100308562026000_9.10.e002873.148","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0093-z"},{"key":"2025100308562026000_9.10.e002873.149","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95200"},{"key":"2025100308562026000_9.10.e002873.150","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.bbrc.2016.01.131","article-title":"Cancer-Associated fibroblasts attenuate cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling","volume":"470","author":"Yan","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"2025100308562026000_9.10.e002873.151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00010"},{"key":"2025100308562026000_9.10.e002873.152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03347-0"},{"key":"2025100308562026000_9.10.e002873.153","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62229"},{"key":"2025100308562026000_9.10.e002873.154","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21635"},{"key":"2025100308562026000_9.10.e002873.155","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2777"},{"key":"2025100308562026000_9.10.e002873.156","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2178"},{"key":"2025100308562026000_9.10.e002873.157","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0945"},{"key":"2025100308562026000_9.10.e002873.158","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0623"},{"key":"2025100308562026000_9.10.e002873.159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118080"},{"key":"2025100308562026000_9.10.e002873.160","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S179189"},{"key":"2025100308562026000_9.10.e002873.161","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.197"},{"key":"2025100308562026000_9.10.e002873.162","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604794"},{"key":"2025100308562026000_9.10.e002873.163","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ijc.30233","article-title":"The TGF\u03b2 pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels","volume":"139","author":"Alsina-Sanchis","year":"2016","journal-title":"Int J Cancer"},{"key":"2025100308562026000_9.10.e002873.164","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2004.01.014"},{"key":"2025100308562026000_9.10.e002873.165","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39065"},{"key":"2025100308562026000_9.10.e002873.166","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13800"},{"key":"2025100308562026000_9.10.e002873.167","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2018.08.001"},{"key":"2025100308562026000_9.10.e002873.168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.05.009"},{"key":"2025100308562026000_9.10.e002873.169","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-38766-6","article-title":"Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation","volume":"9","author":"Mir","year":"2019","journal-title":"Sci Rep"},{"key":"2025100308562026000_9.10.e002873.170","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117933"},{"key":"2025100308562026000_9.10.e002873.171","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903247"},{"key":"2025100308562026000_9.10.e002873.172","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401184"},{"key":"2025100308562026000_9.10.e002873.173","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.02.036"},{"key":"2025100308562026000_9.10.e002873.174","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0542-2","article-title":"Ccl18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling","volume":"15","author":"Lane","year":"2016","journal-title":"Mol Cancer"},{"key":"2025100308562026000_9.10.e002873.175","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/mc.22419","article-title":"Ccl18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway","volume":"55","author":"Wang","year":"2016","journal-title":"Mol Carcinog"},{"key":"2025100308562026000_9.10.e002873.176","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249561"},{"key":"2025100308562026000_9.10.e002873.177","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522"},{"key":"2025100308562026000_9.10.e002873.178","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100308562026000_9.10.e002873.179","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J Clin Invest"},{"key":"2025100308562026000_9.10.e002873.180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308562026000_9.10.e002873.181","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0781-z"},{"key":"2025100308562026000_9.10.e002873.182","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","article-title":"Calreticulin and cancer","volume":"31","author":"Fucikova","year":"2021","journal-title":"Cell Res"},{"key":"2025100308562026000_9.10.e002873.183","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the javelin solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100308562026000_9.10.e002873.184","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2217\/fon-2018-0070","article-title":"Avelumab (anti-PD-L1) in platinum-resistant\/refractory ovarian cancer: javelin ovarian 200 phase III study design","volume":"14","author":"Pujade-Lauraine","year":"2018","journal-title":"Future Oncol"},{"key":"2025100308562026000_9.10.e002873.185","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/annonc\/mdx049","article-title":"A phase 2, randomized, double-blind, placebo-\u00a0controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study","volume":"28","author":"Monk","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100308562026000_9.10.e002873.186","doi-asserted-by":"publisher","DOI":"10.1126\/science.1224922"},{"key":"2025100308562026000_9.10.e002873.187","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-5891"},{"key":"2025100308562026000_9.10.e002873.188","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1474318","article-title":"Low-Dose cyclophosphamide depletes circulating na\u00efve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy","volume":"7","author":"Noordam","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100308562026000_9.10.e002873.189","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025100308562026000_9.10.e002873.190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001136","article-title":"Cxcl13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100308562026000_9.10.e002873.191","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100308562026000_9.10.e002873.192","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059"},{"key":"2025100308562026000_9.10.e002873.193","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: a critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget"},{"key":"2025100308562026000_9.10.e002873.194","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0153"},{"key":"2025100308562026000_9.10.e002873.195","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100308562026000_9.10.e002873.196","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and clinical activity of the programmed Death-Ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women's cancers: a dose-escalation, phase I study","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100308562026000_9.10.e002873.197","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306"},{"key":"2025100308562026000_9.10.e002873.198","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100308562026000_9.10.e002873.199","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"2025100308562026000_9.10.e002873.200","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100308562026000_9.10.e002873.201","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm phases 1 and 2 trial of Niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100308562026000_9.10.e002873.202","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41590-020-0751-0","article-title":"Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy","volume":"21","author":"Yamazaki","year":"2020","journal-title":"Nat Immunol"},{"key":"2025100308562026000_9.10.e002873.203","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123319"},{"key":"2025100308562026000_9.10.e002873.204","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638212","article-title":"Trial Watch: dendritic cell vaccination for cancer immunotherapy","volume":"8","author":"Sprooten","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100308562026000_9.10.e002873.205","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0126"},{"key":"2025100308562026000_9.10.e002873.206","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8040657","article-title":"Development of therapeutic vaccines for ovarian cancer","volume":"8","author":"Chow","year":"2020","journal-title":"Vaccines"},{"key":"2025100308562026000_9.10.e002873.207","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.613773","article-title":"Dendritic cell vaccines in ovarian cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2025100308562026000_9.10.e002873.208","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omto.2019.03.007","article-title":"Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment","volume":"13","author":"Belderbos","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"2025100308562026000_9.10.e002873.209","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030590"},{"key":"2025100308562026000_9.10.e002873.210","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41416-019-0384-y","article-title":"Tumour-reactive T cell subsets in the microenvironment of ovarian cancer","volume":"120","author":"Westergaard","year":"2019","journal-title":"Br J Cancer"},{"key":"2025100308562026000_9.10.e002873.211","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100308562026000_9.10.e002873.212","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.073"},{"key":"2025100308562026000_9.10.e002873.213","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100308562026000_9.10.e002873.214","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025100308562026000_9.10.e002873.215","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1183"},{"key":"2025100308562026000_9.10.e002873.216","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1835"},{"key":"2025100308562026000_9.10.e002873.217","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in car T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100308562026000_9.10.e002873.218","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001162"},{"key":"2025100308562026000_9.10.e002873.219","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41571-021-00490-4","article-title":"Advancing oncolytic virus therapy by understanding the biology","volume":"18","author":"Kaufman","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100308562026000_9.10.e002873.220","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z"},{"key":"2025100308562026000_9.10.e002873.221","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000188"},{"key":"2025100308562026000_9.10.e002873.222","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379"},{"key":"2025100308562026000_9.10.e002873.223","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1889101","article-title":"Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents","volume":"10","author":"Petroni","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025100308562026000_9.10.e002873.224","first-page":"2081","article-title":"CAFs enhance paclitaxel resistance by inducing EMT through the IL\u20116\/JAK2\/STAT3 pathway","volume":"39","author":"Wang","year":"2018","journal-title":"Oncol Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:56:39Z","timestamp":1759506999000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":224,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,13]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/jitc-2021-002873"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002873","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}